CClinicalTrials.gg
CompletedNCT03533049myFAMIUpdated Jul 9, 2020

mHealth Family Self-Management

An interventional study of myFAMI in Transplantation and Pediatric ALL, sponsored by Medical College of Wisconsin. Completed at 1 site in United States. Open to participants aged Up to 100 Years. Per ClinicalTrials.gov, last updated 2020-07-09.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
Up to 100 Years
Sex
All
01

Study summary

This innovative research will address a gap in the literature involving the evaluation of the impact of an individualized family-centered mHealth application to enhance daily post-discharge communication following pediatric transplant. This proposal lays the foundation for future research with myFAMI (self-management intervention) at multiple pediatric transplant centers and builds the science from which to consider post discharge monitoring and decrease cost of care in other pediatric chronic illness populations.

02

Conditions studied

  • Transplantation
  • Pediatric ALL
03

In context

Lead sponsor

Medical College of Wisconsin is the lead sponsor of 540 studies on the registry; 120 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 56 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Pediatric patients:

  1. Has undergone a heart, kidney, or liver transplant being discharged home from the hospital
  2. Has two eligible family members available to answer questions about the patient

Family members will be eligible for participation upon meeting the following inclusion criteria:

  1. is English speaking (to date the instruments being used have been validated for English speaking participants only)
  2. is 18 years of age or older
  3. has a pediatric family member (\< 18 years old) who has undergone a heart, kidney, or liver transplant being discharged home from the hospital.

Exclusion criteria

Exclusion Criteria for the family members are:

  1. presence of significant communication or cognitive impairment that would preclude completion of questionnaires based on self-report; or
  2. the pediatric family member has experienced a previous transplant based on self report.

Participants unable to speak and read English will be excluded due to the lack of resources to develop the app and communicate via FaceTime in different languages. We will recruit family members from three types of transplant populations to allow for sufficient sample in a limited time frame for this complex pediatric surgery and high-risk population.

-

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    myFAMI intervention

    All participants will receive the standard discharge education from their transplant and inpatient care team. Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.

    Other: myFAMI

  • Active comparator
    Control

    Family members assigned to the control group (standard care) will receive standard post-discharge follow-up care consisting of discharge education during the transplant hospitalization and at regularly scheduled appointments instructing families to contact the research nurse with problems or questions.

    Other: myFAMI

Interventions

  • OthermyFAMI

    Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.

06

What researchers measure

Primary outcomes

  1. Improve family coping

    Primary family member receiving myFAMI compared to the primary family member receiving standard post-discharge care will have improved post-discharge coping (primary outcome). Coping will be measured using the post-discharge coping difficulty scale. Post Discharge Coping Difficulty Scale (PDCDS), 10-item measure, Scale 0-10, Measures parental and family member difficulty coping with stress, recovery, self-care and management, support, and confidence, α= .84

    Time frame: 30 days

Secondary outcomes

  1. Decrease healthcare resources

    Primary family member receiving myFAMI compared to the primary family member receiving standard post-discharge care will have decreased use of healthcare resources defined as number of emergency department visits and number or readmissions to the hospital.

    Time frame: 30 days

07

Study locations

1 site
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Publications

  • Lerret SM, Flynn E, White-Traut R, Alonso E, Mavis AM, Jensen MK, Peterson CG, Schiffman R. Acceptability of an mHealth Family Self-management Intervention (myFAMI) for Pediatric Transplantation Families: Qualitative Focus. JMIR Nurs. 2022 Jul 15;5(1):e39263. doi: 10.2196/39263. PubMed 35838761 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03533049
Lead sponsor
Medical College of Wisconsin
Collaborators
National Institutes of Health (NIH)
Responsible party
Stacee Lerret (Associate Professor, Medical College of Wisconsin) — Principal investigator
First posted
May 22, 2018
Start date
Oct 1, 2018
Primary completion
Apr 1, 2020
Completion
May 1, 2020
Last update
Jul 9, 2020

Study contacts

Stacee Lerret, PhD
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion